Cargando…

Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast Cancer

[Figure: see text]

Detalles Bibliográficos
Autor principal:	Mayer, Erica L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352194/ https://www.ncbi.nlm.nih.gov/pubmed/34396228 http://dx.doi.org/10.1016/j.jaccao.2020.05.001

Ejemplares similares

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer
por: Basho, Reva K., et al.
Publicado: (2018)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients
por: Ha, June-Hyung, et al.
Publicado: (2014)

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
por: Laidi, Fatna, et al.
Publicado: (2014)

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
por: Singh, J C, et al.
Publicado: (2014)

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
por: Qin, Tao, et al.
Publicado: (2013)

Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
por: Li, Yan, et al.
Publicado: (2022)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
por: Beasley, Marcie, et al.
Publicado: (2023)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
por: Xie, Yifan, et al.
Publicado: (2021)

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
por: You, Ji Young, et al.
Publicado: (2023)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

Educational Case: HER-2 Positive Breast Cancer
por: Jennings, Julia, et al.
Publicado: (2021)

Evaluation of HER2 Positivity Based on Clinicopathological Findings in HER2 Borderline Tumors in Iranian Patients with Breast Cancer
por: Omranipour, Ramesh, et al.
Publicado: (2023)

Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer
por: Sevcikova, Katarina, et al.
Publicado: (2013)

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
por: Grinshpun, Albert, et al.
Publicado: (2023)

Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2018)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
por: Castagnoli, L, et al.
Publicado: (2017)

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
por: Viansone, A., et al.
Publicado: (2022)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
por: Kaufman, Peter A., et al.
Publicado: (2012)

Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells
por: Hosonaga, Mari, et al.
Publicado: (2014)

Targeted therapy for HER2 positive breast cancer
por: Incorvati, Jason A, et al.
Publicado: (2013)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

Immunotherapies against HER2-Positive Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2023)

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer
por: Ma, Bo, et al.
Publicado: (2016)

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer
por: Maurer, Christian, et al.
Publicado: (2018)

Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
por: Payandeh, Mehrdad, et al.
Publicado: (2017)

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
por: Kurihara, Hiroaki, et al.
Publicado: (2015)

Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer
por: Huai, Jianguo, et al.
Publicado: (2021)

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Yan, Hui, et al.
Publicado: (2020)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
por: Hong, Joohyun, et al.
Publicado: (2022)

(131)I-Labeled Anti-HER2 Nanobody for Targeted Radionuclide Therapy of HER2-Positive Breast Cancer
por: Zhao, Lingzhou, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mfj4q799ifi7a8etrlilar3jpq